JPH0340879A - Medicinal fiber and production thereof - Google Patents

Abstract

PURPOSE:To obtain medicinal fiber having anti-inflammatory action, comprising a specific ethylene-vinyl acetate copolymer, resin containing a specific drug and thermoplastic resin having a higher melting point than the resin by combining so as to make the resin amount to a specific ratio of fiber surface area. CONSTITUTION:A resin consisting essentially of an ethylene-vinyl acetate copolymer having 2-200 melt index is combined with a thermoplastic resin (e.g. polyester or polyamide resin) having a higher melting point than the resin, subjected to conjugate spinning into a form wherein the resin occupies 10-90% fiber surface area, the undrawn yarn (or drawn yarn), immersed in a solution prepared by dissolving one or more drugs selected from methyl salicylate, ibuprofen and piroxicam in vegetable oils and the drug is absorbed in the resin to give medicinal fiber having durability, excellent analgesic and anti-inflammatory action.

Description

[Detailed Description of the Invention] [Industrial Application Field] The present invention relates to a fiber having excellent and long-lasting analgesic and anti-inflammatory effects, and a method for producing the same. [Prior Art] Arthritis, endomyositis. Many of the inflammatory pain diseases, such as keratinitis and keratinitis, occur locally and relatively close to the body surface. Therefore, if it is possible to absorb anti-inflammatory drugs transdermally and obtain higher drug distribution in the inflamed area than in the blood, it would be possible to achieve high local efficacy and side effects such as gastrointestinal disorders that often occur when applied systemically. is expected to reduce the

Currently, ointments containing anti-inflammatory drugs are being evaluated for their usefulness in the treatment of plastic surgery diseases because they are safer than oral preparations and because they are easier to administer to the indirect areas of the limbs. However, due to its formulation properties, ointments do not have uniformity in dosage.
It cannot be said that the purpose is fully met in terms of the safety of the preparation after administration or the durability of the drug's efficacy.

Another preparation that is expected to have the same effect is a patch.

This is generally in the form of a poultice, in which an ointment is applied to one side of a cloth, and compared to ointments, it has a stabilizer, uniformity of dosage, and long-lasting medicinal effect. It is a contaminated preparation.

However, since this preparation basically uses a flat cloth, it is difficult to apply to affected areas with complex external shapes. This disease mostly affects the knees,
It is often seen in joints such as elbows, wrists, and ankles. These parts have complex shapes and constantly change shape during movement. Therefore, in order to obtain a reliable effect during administration, it is necessary to secure the drug well to the affected area with gauze, a wire band, etc., which causes considerable inconvenience when patients use this preparation in their daily lives.

Under these circumstances, there is a desire to develop a formulation or a material constituting the formulation that does not cause any annoyance in daily life and has certain medicinal effects.

[Problems to be Solved by the Invention] As described above, the present invention aims to provide a fiber that further reduces the trouble of fixing the affected area and has excellent and durable analgesic and anti-inflammatory effects, and a method for producing the same. It is something to do.

[Means for solving the problem] That is, the present invention provides a resin containing an ethylene-vinyl acetate copolymer as a main component (hereinafter abbreviated as EVA c) and
A composite fiber made of thermoplastic resin with a higher melting point than E.
It is a medicinal fiber characterized by containing one type of drug recovered from methyl salicylate, ibuprofen, and piroxicam in VAc.

Methyl salicylate was produced by Cahours in 1843 in Cautheria procum, a plant of the Rhododendron family.
Since it was discovered as a main component of the volatile oil of the leaves of B. bes L, it has been reported that it is contained as a glycoside in about 160 plant species. This drug, like other salicylic acid derivatives, has been known for a long time to have fever-lowering, analgesic, and anti-inflammatory effects, and has been used as an oral drug, injection, and patch.

Methyl salicylate has excellent percutaneous absorption among salicylic acid derivatives, and has been reported to be detected in urine 15 minutes after application. Methyl salicylate is also found in internal organs,
When people complain of pain in muscles, joints, or other deep tissues, Counter Iriant (Co
It is applied as an anti-irritant and has the effect of increasing analgesic effect.

Ibuprofen is a non-steroidal analgesic and anti-inflammatory drug that was synthesized by Nicholson and Adams in 1964 and developed by Boots Pure Drug in the UK, and is 16 to 32 times more effective than aspirin. Currently, it is recognized as an extremely useful substance along with indomethacin and ketoprofen.

Ibuprofen's mechanisms of action are said to involve inhibition of prostaglandin biosynthesis, inhibition of vascular permeability, inhibition of leukocyte migration, inhibition of protein thermal denaturation, cell membrane stabilization, and bradykinin release inhibition. It is thought that these effects exert a powerful anti-inflammatory analgesic effect on the inflamed area.

Gastrointestinal disorders caused by nonsteroidal anti-inflammatory drugs are well known, and these disorders can also be observed with ibuprofen. In other words, when this drug is administered orally, nausea, vomiting, angular stomatitis, anorexia, heartburn, and diarrhea may occur.

In rare cases, 5tevens-Johnson syndrome,
Or Lyel I syndrome may occur. However, this was a case of oral administration, and the above-mentioned troubles with transdermal administration have not been reported.

Piroxicam appeared in Japan in 1982 as an acidic nonsteroidal inflammatory agent (hereinafter referred to as N5AID) having the structure shown below.

It is characterized by its strong anti-inflammatory effect and long blood concentration half-life (3
7.5 hours), and was the forerunner of once-daily administration. These long-acting drugs have little fluctuation in blood concentration,
It has the advantage of maintaining effective concentration for a long time. Therefore, once-daily administration is advantageous for non-compliance that tends to occur with long-term administration, such as in invasive rheumatoid arthritis (RA), and is also suitable for morning stiffness characteristic of rheumatism. Currently, NSAID is widely used for inflammatory diseases including infectious diseases and pain diseases due to its anti-inflammatory, analgesic, and antipyretic effects. In particular, it is frequently used for rheumatic diseases, and in particular, it is used as a first-line drug for RA. However, RA is extremely difficult to treat and requires long-term, large-dose administration of NSA[D, so it can be said that side effects are more likely to occur. Therefore, the recent N
The development of SA[D has focused on stronger anti-inflammatory effects and fewer side effects for the treatment of RA. In addition, as a measure to reduce side effects (mainly gastrointestinal disorders),
Improvements have been made in dosage forms such as enteric-coated tablets, sustained-release preparations, prodrugs, and transdermal absorption preparations.

The mechanism of action of piroxicam, like other NASIDs, is thought to be primarily to inhibit prostaglandin (hereinafter referred to as PG) biosynthesis. PG has various physiological activities, and is also known as a mesoeater of inflammation, such as increasing permeability of peripheral blood vessels, vasodilation, and sensitizing the action of carcinogens (bradykinin, etc.). Like other acidic NSAIDs, piroxicam suppresses PC synthesis by inhibiting cyclooxygenase in arachidonic acid metabolism, and exhibits anti-inflammatory and analgesic effects. However, not all inflammatory reactions are caused by PG, and this is where N5AID has its limitations as an anti-inflammatory agent. Furthermore, while inhibition of PG biosynthesis is the main effect, many of the side effects are also thought to be caused through this effect. For example, peptic ulcer, renal disorder, etc. These side effects are caused by oral administration of the drug.

Therefore, if it were possible to absorb this drug transdermally and obtain higher drug distribution in the inflamed area than in the blood, it would be possible to achieve high local efficacy and reduce side effects such as gastrointestinal disorders that often occur when applied systemically. It is expected that

In view of this situation, the inventors selected methyl salicylate, ibuprofen, and pyroquincum as drugs for maintaining medicinal efficacy A, and sought to obtain fibers containing these drugs and having medicinal effects.

As a result of intensive studies to incorporate the above drug into fibers,
A composite yarn consisting of EVAc' and other fiber-forming resins was obtained. Specifically, we focused on the property that EVAc absorbs a large amount of fatty oils, especially vegetable oils, and the property that the above-mentioned drug dissolves in concomitant oils to some extent.
By creating a composite yarn made of and other resins with excellent spinnability and immersing the composite yarn in vegetable oil in which the above-mentioned drug is dissolved, the above-mentioned drug is absorbed into EVAc along with the vegetable oil. It is something. For example, methyl salicylate is a liquid at room temperature, but even when EVAc is immersed in a 100% methyl salicylate solution, EVAc does not swell and its exhaustion rate is extremely low. However, by mixing it with vegetable oil, its exhaustion rate can be greatly increased.

The present invention utilizes such properties to exhaust drug components in EVA c, and therefore contains drugs.

In other words, fibers with medicinal effects were obtained.

In conventional post-processing methods, the target substance is simply coated on the fiber surface, so depending on the conditions, it may not be possible to add a sufficient amount or the substance may fall off due to friction. In addition, recently, a spinning method has been developed that involves adding a target substance into the melted polymer during fiber formation. In this case, it is not suitable because there is a risk of degeneration.

The method according to the present invention is a type of post-processing method that imparts performance to fibers or knitted fabrics, and since the EVAc part of the fiber spontaneously exhausts the chemical solution, the impartment of performance is reliable and easy. It has the feature that it can be done. In addition, since it can basically be exhausted by normal pressure immersion, it has many advantages such as not requiring special equipment such as a high temperature and high pressure cooker.

The EVAc (ethylene-vinyl acetate copolymer) used in the present invention is an ethylene-vinyl acetate copolymer having a vinyl acetate content of 10 to 50% by weight, or a partially saponified EVAC having a similar vinyl acetate content. be. The melt index of both resins is preferably 2 to 200. If the melt index is outside the range, the spinnability will be poor and composite spinning will be difficult. The proportion of vinyl acetate to EVAc is 10 to 50% by weight, preferably 10 to 10%.
is appropriate. E if the proportion of vinyl acetate exceeds 10%
VAc becomes completely amorphous. At first glance, this seems to be compatible with the present invention as the rate and amount of vegetable oil exhaustion increase, but the swelling caused by exhaustion is extremely large.
It is not suitable for the present invention because it has many problems such as a large decrease in physical properties (strength, hardness, etc.) after exhaustion. If the proportion of vinyl acetate is still less than 10%, both the amount of exhaustion and the rate of exhaustion are small, which is not practical. The ratio of vinyl acetate in partially saponified EVA c is also 1 for the same reason as normal EVA c.
0 to 50% by weight, preferably 10 to 10% by weight are suitable.

The other thermoplastic resin that forms the composite yarn with EVA c should preferably have a melting point higher than that of the resin whose main component is EVAc, preferably 280° C. or higher, and be excellent in stringability. Since EVAC has poor spinnability, it can be made into a fiber by combining it with a resin that has excellent spinnability.

Moreover, if the melting point is 200° C. or less, it is not preferable because the application to clothing etc. becomes difficult due to insufficient heat resistance, and the applications are somewhat limited. Polyester containing polyethylene terephthalate or polybutylene terephthalate as a main component, polyamide containing nylon 6, nylon 6.6, metaxylene diamine nylon as a main component, and the like are suitable as the resin.

The vegetable oil used in the present invention is a medium for dissolving the drug and introducing it into EVAc, and specifically, it includes avinis oil, amyris oil, angelica oil, amplified seed oil, ylang-ylang oil, elemi oil, and oakmoss oil. , Oyutica oil, Origanum oil, Orris oil, Cassie oil, Cananga oil, Chamomile oil, Kayabu oil, Calamus oil, Galbanum oil, Guayatsk wood oil, Grapefruit oil, Costas oil, Viyakudan oil, Citrus oil, Jasmine oil , ginger oil,
Sweet orange oil, Styrax oil, spearmint oil, cedarwood oil, geranium oil, davana oil, tansy oil, turpentine oil, tuberose oil, neroli oil, pine oil, patchouli oil, mustard oil, vanilla oil, balsam/copaipa oil, balsam・Tulu oil, balsam Peruvian oil,
Palmarosa oil, cilantro oil, bitter almond oil, bitter orange oil, cypress oil, vetiver oil, peppermint oil, pennyroyal oil, perilla oil, bergamotsu ura, benzoin oil, bois de rose oil, aromatic oil, mandarin oil,
Eucalyptus oil, lavandin oil, lavender oil, lemon oil,
Natural vegetable oils such as lemongrass oil, rose oil, and rosemary oil, and synthetic compounds that imitate the main components of these natural vegetable oils, such as terpenes such as α-pinene, β-pinene, camphene, limonene, myrcene, and β-caryophyllene. Hydrocarbons, linalool, geraniol, nerol, citronellol, lavender oil, myrcenol, α-terpineol, 2-menthol, berneol, nopol, isobornylcyclohexanol, farnesol, nerolidol, santalol, cedrol, pacurial alcohol, etc. Terpene alcohol, benzyl alcohol,
Phenethyl alcohol, γ-phenylpropyl alcohol, cinnamic alcohol, anth alcohol, d-α-dimethylphenethyl alcohol, α-phenylethanol,
Alcohols such as β-phenylethyldimethylcarbinol, phenoxyethanol, and patchon, diphenyl ether isosafroeugenol, p-methylanryl, anethole, eugenol, isoeugenol, methyleugenol, methylisoeugenol, benzylisoeugenol, safrole, isosafrole, methyl - Phenols and their derivatives such as β-naphthyl ether, ethyl-β-naphthyl ether, heptanal, octanal, nonanal, decanal, undecanal,
Aliphatic aldehydes such as dodecanal, 2-methylundecanal, tridecanal, tetradecanal, hexadecanal, trans-2-hexenal, 2,6-nonanegenal, citral, citronellal, hydroxycitronellal, perilaldehyde, Terpene aldehydes such as citronellyloxyacetanedehyde, lyral, sinensal, benzaldehyde, phenylacetaldehyde, 3-phenylpropionaldehyde,
cinnamaldehyde, α-amyl cinnamaldehyde,
α-hexylcinnamaldehyde, anisaldehyde,
Aromatic aldehydes such as cumin aldehyde, piperonal, cyclamen aldehyde, pt-butyl-α-methyldihydrocinnamdehyde, nokuniline, pulbonal, citral dimethyl acetal, citral diethylacecur, hydroxycitronellal dimethyl acetal, Acetals such as phenylacetaldehyde dimethyl acetal, 2-heptanone, 3-octanone, 2
- Aliphatic ketones such as octanone and 2-undecanone, terpene ketones such as carvone, menthone, and prevone, p-
Methylacetophenone, p-methoxyacetophenone,
Aromatic ketones such as benzophenone, penzolidenacetone, anisyl acetone, p-hydroxybenzylacetone, 2-acetonaphthone, α-9β-1γ-ionone, α
-n, β-n, γ-n methylionone, αβ-1γ-isomethylionone, α-9βγ-ilone, α-2β-damascenone, α-1βγ-damascone, theaspiran, theaspiran, ezran, rosefuran, nootkatone,
α-vetivone, cis-jasmone, dihydrojasmone, methyl jasmonate, methyl dihydrojasmonate jasmine lactone, maltol, cyclotene, furaneol, etc. cycloaliphatic ketones, cycloaliphatic ethers, cycloaliphatic lactones, muscone, civetone, cyclopenta Decanone, cyclopentadecanolide, ambrettolide, cyclopentadecanolide, ethylene brasilard, 12-oxahexadecanolide, 11-oxahexadecanolide, lO
- Macrocyclic ketones such as oxahexadecanolide, lactones, muskkenlen, muskketone, musk ampret, muskene, celestride, fantolide, tonalide,
Synthetic musk such as boraxolide, rose oxide, oxide ketone, linalool oxide, 1.8 noneol,
Bicyclodihydrohomopher, cyclic ethers such as nesyl oxide, indole, skatole, 6-methylquinoline, 7-methylquinoline, 6-isopropylquinoline, 2-methyltetrahydroquinoline, 6-methyltetrahydroquinoline, 2-isobutylthiazole, 2 -Heterocyclic compounds such as furylmethanethiol, 2-methylpyrazine, 2.5-dimethylpyrazine, 2.3.5-)trimethylpyrazine, esters of aliphatic acids such as geranyl formate, benzyl formate, ethyl acetate, and geranyl acetate. , methyl benzoate, isoamyl benzoate, ethyl anisate, methyl salicylate, methyl carnamate, and other esters of aromatic acids.

Next, the method for manufacturing the fiber of the present invention will be explained.

FIG. 1 schematically shows a spinning apparatus for obtaining the fiber of the present invention.

One of the two melt extruders 1 contains a resin (A) whose main component is EVAc, and the other 2 has a resin (A) with a higher melting point than that of (A).
It is filled with resin (B) which has excellent stringability. The polymer streams melted and extruded by the extruder are each accurately metered by a gear pump and sent to the spinning head. The two types of polymer streams are combined by a pack fitting installed in the head, and then discharged from a spinneret and turned into fibers.

The composite form of resin (^) and (B) is based on the result that resin A has a surface area of 100% of the yarn surface area. 10-90%
It has been found that any form that accounts for preferably 20 to 80% is sufficient.

Several examples of composite forms of EVAc and other polymers according to the invention are shown in FIG. As shown in (6) in Figure 2, resin (A) and (
When kneading B), a static mixer is used. Static mixers include the Kenics static mixer, Toshiku Co., Ltd.'s /%i mixer, and Charles & Ross.
These include the company's Ross I Niss G (ISG) mixer. Care must be taken as the degree of kneading varies depending on the structure and number of elements. Considering the exhaustion and sustained release of the drug solution, it seems that 25 layer divisions would be good.

The spinning speed is loooom/m+n ~ similar to general fibers.
Do it at 2000a/sin or 3G00~5100
Either a/g+in high speed spinning may be performed. EV
Ac alone lacks stringiness, but PET, P
By combining it with BT, nylon, etc., even high-speed spinning can be performed without any problem. Depending on the composite resin or composite form, separation of the two resins may occur during stretching, so high-speed spinning is effective in that case. If this is not the case, it is possible to obtain a yarn with high strength by spinning at a normal spinning speed and ensuring stretching.

In order to exhaust the associated oil solution of the drug into the fibers, woven fabric, or fabric after spinning or drawing, the yarn or fabric is immersed during melting under normal pressure or under pressurized pressure. When a chemical solution exhaustion rate of EVAc is required at normal pressure, a method using pressurization is preferable. The exhaustion rate can also be increased by heating. When heating, it is necessary to carry out heating within a range that does not cause volatilization or denaturation of vegetable oil, elution of EVAc, etc.

[Effects of the Invention] The medicinal fibers of the present invention have excellent transdermal absorbability and are able to absorb and retain methyl salicylate, ibuprofen, or piroxicam, which are analgesic and anti-inflammatory agents, in the fibers through post-processing. This enables an unprecedented new form of preparation with analgesic and anti-inflammatory effects, and frees patients from the inconvenience of using patches or ointments.

[Example] The present invention will be specifically described below with reference to Examples.

Example! 10φ of polyethylene terephthalate to which 0.5% by weight (hereinafter abbreviated as VT) of Ti1t with [η]=0.65 was added.
Extruded with an extruder, while vinyl acetate 20wt% Ev
Ac was extruded from a 10φ extruder, and after weighing a predetermined amount, it was forced into a spinning bag, discharged from a μ-hole nozzle, and subjected to belly spinning at a spinning speed of 1000 m/sin.

The cross section of the composite yarn is as shown in Figure 3, and the total fiber surface area is 2
It is composited so that EVA c accounts for 0%.

The spun yarn was stretched on a roller plate to a 75 denier 2
A multifilament with 4 filaments was obtained.

The drawn yarn was knitted using a tube knitting machine to obtain a tube knitted fabric with a diameter of 7.5 cm. After completely removing the oil from the tubular knitted fabric with detergent,
vt % methyl salicylate-6 in a pepper oil solution at 30°C.
It was immersed for 0 minutes. After soaking, soak the knitted fabric in a warm solution of neutral detergent (approx.
The chemical solution adhering to the knitted fabric and between the stitches was completely removed. Thereafter, it was washed with water, dehydrated, and air-dried. - After being left to air dry overnight, the weight increase rate was measured and was 180%. Furthermore, the amount of methyl salicylate contained per tg of tubular knitted fabric before exhaustion was loomg. This is approximately the same drug concentration as commercially available patches.

Example 2 10% of polybutylene terephthalate with [η]=0.68
Extruded from a φ extruder, while containing vinyl acetate! After extruding 25vt% EVAc from a 10φ extruder and weighing a predetermined amount of each, it was forced into a spinning pack and discharged from a round hole nozzle, and high-speed composite spinning was performed at a spinning speed of 3500m/+++in to produce a 90-denier 24-filament multifilament. I got it. The cross section of the composite yarn is as shown in FIG. 4, and the composite yarn was composited so that EVAc occupied 30% of the total fiber surface area. The composite yarn was false twisted under normal conditions. The false-twisted yarn was shaped into a general shape by a setter and immersed in 10 vt% methyl salicylate-olive oil overnight at 30° C. for 60 minutes. After soaking, it was washed with detergent (approximately 30° C.) in the same state as before, and then washed with water. After washing with water, it was left to air dry for a day and then wound back onto a bobbin.

In the system thus obtained, 120 B of methyl salicylate was exhausted per 111 g of pre-exhausted filaments.

Using the methyl salicylate exhaust thread, width 15 cm, length 1
A rubber knitted fabric with a small density of 0 cm was made. Because the wood is knitted with rubber, it has excellent elasticity and low density, so when it is wrapped around the hands and feet, the main knitted fabric is cut out to an appropriate size and used to wrap around the knees, elbows, shoulders, hips, etc. It was applied to a part of the body that has a complex shape, such as the neck, and constantly changes its shape due to exercise, but it did not shift or fall off even with exercise, and it was not particularly noticeable, and it felt good to wear. .

Comparative Example I Composite Mffl of EVAc and polyethylene terephthalate
The ratio was 90:1G, and the ratio of EVAc to the fiber surface was 95%, and belly-to-belt spinning was attempted. However, the shaking of the yarn on the nozzle surface did not subside and the spinning condition was poor.

Comparative Example 2 An attempt was made to obtain a composite yarn using EvAc with a melt index (M) of 300 in the same manner as in Example 1, but single yarn breakage occurred frequently during spinning, making winding difficult. Stretchability was extremely poor, with single yarn breakage and fluffing occurring at times.

Example 3 The drawn yarn obtained in Example 1 was knitted using a tube knitting machine to produce a tube knitted fabric with a diameter of 7.5 cm. After completely removing the oil content of the tubular knitted fabric with a detergent, it was immersed in a 5 wt % ibuprofen-pepper oil solution at 30° C. for 60 minutes. After soaking,
The knitted fabric was washed in a warm neutral detergent solution (approximately 30° C.) to completely remove the chemical solution adhering to the knitted fabric and between the stitches. Thereafter, it was washed with water, dehydrated, and air-dried. - After being left overnight and air-dried, the weight increase rate was measured and was 195%. In addition, the amount of ibuprofen contained per tg of tube knitted fabric before exhaustion is 30a+
It was g.

Example 4 Using the false-twisted yarn obtained in Example 2, the false-twisted yarn was shaped into a general shape using a recognition machine and immersed in a 5vt% ibuprofen-olive oil solution at 30°C for 60 minutes. After soaking, the whole product was washed with detergent (approximately 30°C) and then with water. After washing with water, it was left to air dry for a day and then wound back onto the bobbin.

In the system thus obtained, 35 mg of ibuprofen was exhausted per 111 g of electrotype before exhaustion. Using the ibuprofen exhaustion thread, a medium 15 cm 1 length 4 (tea
I made a rubber knitted fabric with a small density. Since the main knitted fabric is a rubber knit, it has high elasticity and low density, so when I applied it to my hands and feet, I didn't feel any discomfort.

The main knitted fabric was cut to an appropriate size and applied to areas with complex shapes such as knees, elbows, shoulders, hips, and necks that constantly change shape due to exercise. There was nothing particularly noticeable about it, and it felt good to wear.

Example 5 The drawn yarn obtained in Example 1 was knitted with a tube knitting machine to a diameter of 7.5 mm.
A tubular knitted fabric of cm was obtained. After completely removing the oil component of the rR knitted fabric with detergent, 5wt% piroxicam-Hatuka oil solution A3
It was immersed in 0°C for 60 minutes. After soaking, the knitted fabric was covered in a warm neutral detergent solution (approximately 30° C.) to completely remove the chemical solution adhering to the knitted fabric and between the stitches.

Thereafter, it was washed with water, dehydrated, and air-dried. - After being left overnight and air-dried, the weight increase rate was measured and was 210%.

L before exhaustion again! The amount of ibuprofen contained in one knitted fabric was 45 mg.

The main knitted fabric was cut to an appropriate size and applied to areas with complex shapes such as knees, elbows, shoulders, hips, and necks that constantly change shape due to exercise. There was no problem, and it was not particularly noticeable, and it felt good to wear.

Example 6 The false twisted yarn obtained in Example 2 was formed into a general shape using a twisting machine and immersed in 5wk% piroxicamum olive oil at 30°C for 60 minutes. After soaking, it was washed with detergent (approximately 30°C) in the same state as before, and then washed with water.

After washing with water, it was left to air dry for a day and then wound back onto a bobbin. In the system thus obtained, 3
5B of piroxicam had been exhausted.

Using the piroxicam suction thread, width 15 cm, length 10 cm
A rubber fabric with a low density of a+ was made. Since the main knitted fabric is a rubber knit, it has high elasticity and low density, so when I wrapped it around my hands and feet, I didn't feel any discomfort.

[Brief explanation of drawings]

FIG. 1 is a schematic diagram of a spinning device for obtaining the fiber of the present invention;
FIG. 2 is a diagram showing the composite form of the composite fiber of the present invention, and FIGS. 3 and 4 are cross-sectional photographic reproductions of the composite fiber used in Examples, respectively. Fig. 1 Melt extruder ■ Hand pump ■ Gear pump ■ Spinneret Metal spinning head Diagram (1) (2) (3) (4) (5) (6) (7 (8) (9) (10) (11) (12) Fig. Cross-sectional photographic reproduction of the thread according to Example 1 Example 21 Cross-sectional photographic reproduction of the twisted thread

Claims (2)

[Claims] (1) Consisting of a resin whose main component is an ethylene-vinyl acetate copolymer with a melt index of 2 to 200 and a thermoplastic resin having a higher melting point than the resin, and the ratio of the former resin to the surface area of the fiber is 10-90%,
A medicinal fiber having excellent analgesic and anti-inflammatory effects, characterized in that the former resin contains one kind of drug selected from methyl salicylate, ibuprofen, and piroxicam. (2) Spun yarn or drawn yarn obtained by composite spinning a resin whose main component is an ethylene-vinyl acetate copolymer having a melt index of 2 to 200 and a thermoplastic resin having a higher melting point than the resin. The yarn is immersed in a solution in which one drug selected from methyl salicylate, ibuprofen, and piroxicam is dissolved, and the solution is absorbed into the former resin, thereby causing the drug to be absorbed into the fiber. A method for producing medicinal fibers having excellent analgesic and anti-inflammatory effects.